Drug intelligence / Profile preview

AeroVeil

Development stage: Preclinical
Lead developer: Luna Labs
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Intraperitoneal

Overview

AeroVeil is a sprayable hydrogel developed by Luna Labs, currently in preclinical development. It is designed to reduce the incidence of abdominal adhesions and enhance wound healing following surgical procedures, with a specific focus on post-cesarean uterine recovery. The hydrogel is applied as a spray that forms a protective barrier over the surgical site, preventing tissues from sticking together during the healing process and minimizing post-operative scar formation. By providing a physical barrier and a supportive matrix, AeroVeil aims to improve surgical outcomes and reduce complications associated with adhesion formation.

Brand names: AeroVeil
Other names: AeroVeil Sprayable Hydrogel

Beyond the preview

Go deeper on AeroVeil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AeroVeil.

Explore the full profile